Samsung Biologics to Acquire PolyPeptide in All-Cash Deal, Expanding Global Manufacturing
PolyPeptide's specialized peptide expertise and global multi-site network to strengthen Samsung Biologics' multi-modality and global manufacturing excellence.
Contract Development And Manufacturing Organizations (CDMO)
Olon Expands Concord, Ohio Site, Doubling US Manufacturing Capacity
Olon has completed a major expansion at its Concord, Ohio facility, doubling production capacity and strengthening the site's role as a US manufacturing hub within its global development network.
Evonik Invests $100 Million in US API Production
Evonik is modernizing the API production at its Tippecanoe site in the US Over the next five years, the company will invest $100 million in upgrading key plant components.
Siddharth Mittal Appointed as Managing Director & CEO of Syngene International
Syngene International announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.
Symeres and Axxam Unite Drug Discovery Platforms Under Single Scientific Chief
Russell Thomas, who has held senior roles at both organisations, takes on the joint CSO position as Symeres and Axxam push to offer clients a single pipeline spanning target screening to IND-ready drug candidates.
Former Bachem Executive Torsten Woehr to Become CEO of Rentschler
Rentschler Biopharma has appointed Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.
Adragos and Towa to Produce 1.5 Billion Tablets a Year
CDMO Adragos Pharma Kawagoe and Towa Pharmaceutical have agreed to a manufacturing partnership that will nearly triple solid-dosage capacity, shoring up Japan's fragile generics supply chain.
Lonza Expands Visp Site to Meet Demand in ADCs
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market.
Axplora Repositions European Site on High-Potency Drugs as India Takes Over UDCA Production
Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
Northway Biotech Invests €61 Million in Vilnius Cell Therapy Manufacturing Center
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
Asahi Kasei Life Science Licenses Novel ADC Technology From The Noguchi Institute
Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
CordenPharma Acquires AmbioPharm to Expand Peptide API Capacity
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Catalent and Elpida Therapeutics Join Forces for Gene Therapy Scale-Up
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
Alcami Completes Tjoapack Acquisition to Bolster Global Packaging Scale
Alcami completes its acquisition of Tjoapack, creating a 1,400-strong CDMO with over one million square feet of operations across the US and the Netherlands, adding European packaging scale and QP release services.
Hongene Backs SiranBio's RNAi Pipeline with Advanced CDMO Support
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Piramal Pharma Solutions Expands CDMO Capabilities at Michigan Facility
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
Symeres Appoints Henning Steinhagen as CEO
Symeres, a transatlantic CRDMO for drug discovery and development, announced the appointment of Henning Steinhagen as Chief Executive Officer.
Siegfried Secures Antitrust Green Light for US and Australia Drug‑Substance Site Takeover
All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
India’s CDMO Strength: Powering Global Chemical Innovation
India’s CDMO sector is rapidly advancing: stronger R&D, complex chemistry, digitalization, and efficiency gains. Astec boosts this with new R&D centers, automation, and global‑standard operations.
Evonik Invests €80 Million in Slovakia
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million
Brenntag Introduces New Biopharma Brand
Byphar is Brenntag's new biopharma-focused brand designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing.
Ofichem Unifies Brands Under Single CDMO and Pharmaceutical Supplier
Ofichem has unified its six brands under the single Ofichem name, creating a fully integrated, family-owned CDMO and pharmaceutical supplier.
Prange Pharma Launches Aprilia Animal Health CDMO After MSD Site Acquisition
Prange Pharma has completed its acquisition of MSD Animal Health’s Aprilia site in Italy, which will now operate as Aprilia Animal Health, a new European CDMO platform for the animal health sector.
Outsourced Biomanufacturing
On Demand | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.
Adragos Pharma Completes Acquisition of Sanofi’s Sterile Fill-Finish Site in France
Adragos Pharma has acquired Sanofi’s Maisons-Alfort sterile fill-finish site in France, expanding its European manufacturing network and prefilled syringe capabilities.
Samsung Biologics Acquires GSK’s Manufacturing Facility in Maryland, US
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry
As pharmaceutical production methods continue to evolve, flow chemistry is emerging as a safer, more scalable and selective alternative to conventional batch manufacturing.
Cambrex Advances US and European Expansions
Cambrex is advancing its $150 million investment to expand API manufacturing in Iowa and enhance R&D and manufacturing capabilities in Milan, strengthening its services in the US and Europe.
LGM Pharma Boosts US Manufacturing with Additional $9 Million Investment
LGM Pharma invests an additional $9 million to expand US manufacturing, bringing total investment to $15 million across its Texas and Colorado facilities.
Ice Pharma Expands Beyond APIs to Create New Bile Acid Markets
Ice Pharma recently announced a strategic expansion beyond its core API business, positioning the company to compete in higher-value finished dosage, nutraceutical, and specialty excipient markets.
CordenPharma Colorado Partners with BioMed Realty on Peptide Development Lab Expansion
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site in Italy
$60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy.
Sandoz Creates New Global Biosimilar Unit
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer
Symbiosis Pharmaceutical Services has appointed experienced commercial leader Joanne Anderson as Chief Commercial Officer to drive global growth following recent capacity investments and expansion plans.
Lonza Divests Capsules & Health Ingredients Business for $3 Billion
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of $3 billion (CHF 2.3 billion).
Saltigo GmbH
Serán Bioscience, LLC
Quotient Sciences
Prange Pharma
Godrej Astec LifeSciences Limited (Astec Life)
Rentschler Biopharma SE
Symbiosis Pharmaceutical Services
WeylChem International GmbH
OneSource Specialty Pharma Limited
Abzena
Kurma Partners
Syngene International Ltd.
Informa Markets
ICIG
CordenPharma International
Evonik Industries AG
WuXi AppTec
AmbioPharm, Inc.
SchüllerConsulting
Ice Pharma
Navin Molecular
Ferak Berlin GmbH
Frost & Sullivan
CatSci Ltd.
Forma Life Sciences
SK Pharmteco
Avantor
Aenova Holding GmbH
Fraser Dove International
Lonza AG
Axplora
Agno Pharma
HAS Healthcare Advanced Synthesis SA
Samsung Biologics
WittKiefer
IDT Biologika GmbH
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Mabion
GLSyntech LLC
Patheon Italia
ISPE D/A/CH e.V.
Curia
Haltermann Ltd.
Arthur D. Little
Adragos Pharma
Codexis
Northway Biotech
Solvias AG
CHEManager International c/o Wiley-VCH GmbH
DSM Pharmaceutical Products